PATENT CLAIM ANALYSIS

Application Number: 16245735
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-07
Patent Classification: ["530", "317000"]

Abstract:
Melanocortin receptor-specific cyclic peptides of the formula where R 1 , R 3 , R 4 , R 9  and R 10  are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.

Claim (Index 1):
A cyclic peptide of the structural formula: including all enantiomers, stereoisomers or diastereoisomers thereof, or a pharmaceutically acceptable salt of any of the foregoing,\n wherein:\n R 1  is H\u2014 or a C 1  to C 7  acyl group, wherein the C 1  to C 7  comprises a linear or branched alkyl or a cycloalkyl or both a linear alkyl and a cycloalkyl; \n R 3  is \u2014H, \u2014CH 3  or \u2014CH 2 \u2014, and if it is \u2014CH 2 \u2014 forms with R 4  a ring of the general structure \n \n R 4  is \u2014H, \u2014(CH 2 ) z \u2014 if R 3  is \u2014CH 2 \u2014, and if it is \u2014(CH 2 ) z \u2014 forms the ring with R 3 , provided that if R 11  is not H, then the carbon atom to which R 11  is bound is \u2014CH\u2014, or R 4  is \u2014(CH 2 ) w \u2014R 12 \u2014(CH 2 ) w \u2014R 13 , wherein any H in either (CH 2 ) w  is optionally substituted with \u2014(CH 2 ) w \u2014CH 3 , but, if R, is CH 3 \u2014(C\u2550O)\u2014 and R 9  is C(\u2550O)\u2014OH or C(\u2550O)\u2014NH 2 , then excluding:\n \u2014(CH 2 ) 2 \u2014 but only if R 3  is \u2014CH 2 \u2014 and forms an unsubstituted pyrrolidine ring with R 3  and R 10  is \u2014CH 2 \u2014C(\u2550O)\u2014NH\u2014(CH 2 ) 4 , \u2014(CH 2 ) 2 \u2014C(\u2550O)\u2014NH\u2014(CH 2 ) 3  or \u2014(CH 2 ) 3 \u2014NH\u2014C(\u2550O)\u2014(CH 2 ) 2 , \n \u2003but only if R 10  is \u2014CH 2 \u2014C(\u2550O)\u2014NH\u2014(CH 2 ) 4 , \u2014(CH 2 ) 2 \u2014C(\u2550O)\u2014NH\u2014(CH 2 ) 3  or \u2014(CH 2 ) 3 \u2014NH\u2014C(\u2550O)\u2014(CH 2 ) 2 , and \u2003but only if R 10  is \u2014CH 2 \u2014C(\u2550O)\u2014NH\u2014(CH 2 ) 3 , \u2014(CH 2 ) 2 \u2014C(\u2550O)\u2014NH\u2014(CH 2 ) 3 , \u2014CH 2 \u2014C(\u2550O)\u2014NH\u2014(CH 2 ) 4  or \u2014(CH 2 ) 2 \u2014C(\u2550O)\u2014NH\u2014(CH 2 ) 4 ; R 9  is H, \u2014C(\u2550O)\u2014OH, \u2014C(\u2550O)\u2014N(R 15a )(R 15b ) or \u2014C(\u2550O)\u2014(CH 2 ) w -cycloalkyl; R 10  is\n \u2014(CH 2 ) x \u2014C(\u2550O)\u2014NH\u2014(CH 2 ) y \u2014, \n \u2014(CH 2 ) x \u2014NH\u2014C(\u2550O)\u2014(CH 2 ) y \u2014, \n \u2014(CH 2 ) x \u2014C(\u2550O)\u2014(CH 2 ) z \u2014C(\u2550O)\u2014(CH 2 ) y \u2014, \n \u2014(CH 2 ) x \u2014C(\u2550O)\u2014NH\u2014C(\u2550O)\u2014(CH 2 ) y \u2014, or \n \u2014(CH 2 ) x \u2014NH\u2014C(\u2550O)\u2014NH\u2014(CH 2 ) y \u2014 \n R 11  is \u2014H or \u2014R 12 \u2014(CH 2 ) w \u2014R 13 ; R 12  is optionally present, and if present is\n \u2014O\u2014, \n \u2014S\u2014, \n \u2014NH\u2014, \n \u2014S(\u2550O) 2 \u2014, \n \u2014S(\u2550O)\u2014, \n \u2014S(\u2550O) 2 \u2014NH\u2014, \n \u2014NH\u2014S(\u2550O) 2 \u2014, \n \u2014C(\u2550O)\u2014, \n \u2014C(\u2550O)\u2014O\u2014, \n \u2014O\u2014C(\u2550O)\u2014, \n \u2014NH\u2014C(\u2550O)\u2014O\u2014, \n \u2014O\u2014C(\u2550O)\u2014NH\u2014, \n \u2014NH\u2014C(\u2550O)\u2014, or \n \u2014C(\u2550O)\u2014NH\u2014; \n R 13  is H, \u2014CH 3 , \u2014N(R 15a )(R 15b ), \u2014NH\u2014(CH 2 ) z \u2014N(R 15a )(R 15b ), \u2014NH\u2014C(\u2550NH)\u2014N(R 15a )(R 15b ), \u2014NH\u2014C(\u2550O)\u2014N(R 15a )(R 15b ), \u2014O(R 15a ), \u2014(R 15a )(R 15b ), \u2014S(\u2550O) 2 (R 15a ), \u2014C(\u2550O)\u2014O(R 15a ), \u2003wherein any ring in R 13  is optionally substituted with one or more ring substituents, and when one or more are present, are the same or different and independently hydroxyl, halogen, sulfonamide, alkyl, \u2014O-alkyl, aryl, \u2014O-aryl, C(\u2550O)\u2014OH, or C(\u2550O)\u2014N(R 15a )(R 15b ); R 15a  and R 15b  are each independently H or a C 1  to C 4  linear or branched alkyl chain; R 17  is H, \u2014C(\u2550O)\u2014OH, or \u2014C(\u2550O)\u2014N(R 15a )(R 15b ); w is in each instance independent 0 to 5; x is 1 to 5; y is 1 to 5; and z is in each instance independently 1 to 5.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 99.0
- Lexical Diversity: 1.56757
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13311817', '13311824', '14328995', '15214845', '14514472']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7474905427754696
- 35 USC 102 Novelty (BERT): 0.5634502211293088
- Combined Prediction Score: 0.7290865106108535
- Mean Citation Score: 423.7474
- Max Citation Score: 446.31934
- Similarity Product: 384.7978695532536

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test